PIPStek LLC, a Subsidiary of Sonendo, Files Patent Infringement Lawsuit Against BIOLASE
January 04 2023 - 4:20PM
Business Wire
Lawsuit Asserts BIOLASE® Waterlase® Laser
Infringes Two PIPStek Patents
Sonendo, Inc. (NYSE: SONX), a leading dental technology company
and developer of the GentleWave® System, today announced that its
subsidiary PIPStek LLC has filed a patent infringement lawsuit
against BIOLASE, Inc. in the U.S. District Court for the District
of Delaware. In the lawsuit, PIPStek asserts infringement of
PIPStek’s US patents 11,426,239 and 11,350,993 by BIOLASE’s
Waterlase laser.
PIPStek is a wholly owned subsidiary of Sonendo. Sonendo
acquired PIPStek and all its intellectual property in 2017,
including PIPStek’s laser technologies for dental applications.
“Sonendo and PIPStek are committed to protecting our
intellectual property and any future application of our
intellectual property and investments in innovation,” said Bjarne
Bergheim, president and chief executive officer of Sonendo. “We
have not commercialized the PIPStek laser technologies because of
our confidence that the GentleWave System is a better, more
effective option for doctors and patients than laser-driven or
traditional root canal disinfection. However, we have made
significant investments in our broad intellectual property
portfolio, and we will defend those investments and options for
future product development and use. We feel strongly that the Court
will find in our favor and provide a remedy to address BIOLASE’s
infringing activities.”
Sonendo and its subsidiaries have more than 200 patents and
pending patent applications created since the Company’s inception
in 2006, with new patents being filed each year.
About Sonendo
Sonendo is a commercial-stage medical technology company focused
on saving teeth from tooth decay, the most prevalent chronic
disease globally. Sonendo develops and manufactures the GentleWave®
System, an innovative technology platform designed to treat tooth
decay by cleaning and disinfecting the microscopic spaces within
teeth without the need to remove tooth structure. The system
utilizes a proprietary mechanism of action, which combines
procedure fluid optimization, broad-spectrum acoustic energy, and
advanced fluid dynamics, to debride and disinfect deep regions of
the complex root canal system in a less invasive procedure that
preserves tooth structure. The clinical benefits of the GentleWave
System when compared to conventional methods of root canal therapy
include improved clinical outcomes, such as superior cleaning that
is independent of root canal complexity and tooth anatomy, high and
rapid rates of healing and minimal to no post-operative pain. In
addition, the GentleWave System can improve the workflow and
economics of dental practices and offers patients an effective,
less invasive, and less painful alternative to traditional root
canal therapy.
Sonendo is also the parent company of TDO® Software, the
developer of widely used endodontic practice management software
solutions, designed to simplify practice workflow. TDO Software
integrates practice management, imaging, referral reporting and
CBCT imaging, and offers built-in communication with the GentleWave
System.
For more information about Sonendo and the GentleWave System,
please visit www.sonendo.com. To find a GentleWave doctor in your
area, please visit www.gentlewave.com.
Forward Looking Statements
In addition to background and historical information, this press
release contains "forward-looking statements" based on Sonendo's
current expectations, forecasts and beliefs, including Sonendo’s
expectations regarding how the court will rule on the company’s
complaint against BIOLASE. These forward-looking statements are
subject to inherent uncertainties, risks, and assumptions that are
difficult to predict, including risks generally associated with
litigation and other risks and uncertainties described more fully
in the company's Annual Report on Form 10-K for the year ended
December 31, 2021 filed with the U.S. Securities and Exchange
Commission (SEC) on March 23, 2022 under the sections titled "Risk
Factors" and "Management’s Discussion and Analysis of Financial
Condition and Results of Operation”, as well as any reports that we
may file with the SEC in the future. Forward-looking statements
contained in this announcement are based on information available
to Sonendo as of the date hereof. Sonendo undertakes no obligation
to update such information except as required under applicable law.
These forward-looking statements should not be relied upon as
representing Sonendo’s views as of any date subsequent to the date
of this press release and should not be relied upon as prediction
of future events. In light of the foregoing, investors are urged
not to rely on any forward-looking statement in reaching any
conclusion or making any investment decision about any securities
of Sonendo.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005947/en/
Investor Contact: Gilmartin Group Greg Chodaczek
IR@Sonendo.com
Sonendo (NYSE:SONX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonendo (NYSE:SONX)
Historical Stock Chart
From Apr 2023 to Apr 2024